Reductions in mortality seen in association with ACE inhibitors, beta-blockers, thiazide diuretics
WEDNESDAY, Sept. 1, 2021 (HealthDay News) — Antihypertensive medication use is associated with a reduction in cancer-specific mortality among patients diagnosed with colorectal cancer (CRC), according to a study published in the August issue of Cancer Medicine.
Rajesh Balkrishnan, Ph.D., from the University of Virginia in Charlottesville, and colleagues conducted a noninterventional, retrospective analysis of 13,982 patients aged 65 years and older with CRC diagnosed from Jan. 1, 2007, to Dec. 31, 2012, in the Surveillance, Epidemiology, and End-Results Medicare database. The authors examined the association between antihypertensive drug utilization and the American Joint Committee on Cancer stage I to III CRC mortality rates.
The researchers found that the use of antihypertensive drugs was associated with decreased cancer-specific mortality among patients diagnosed with CRC (hazard ratio, 0.79). Angiotensin-converting enzyme inhibitors, beta-blockers, and thiazide diuretics were associated with decreased mortality (hazard ratios, 0.84, 0.83, and 0.83, respectively). There was also an association between adherence to antihypertensive therapy and reduced cancer-specific mortality (hazard ratio, 0.94).
“The results of this study are novel and suggest future research analyzing the application of antihypertensives as a tool to improve cancer-related mortality,” the authors write.
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus
Postoperative Complications Elevated for Patients With Systemic Lupus Erythematosus
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing